MIR4500: A Potential Drug Target and Biomarker (G100616182)
MIR4500: A Potential Drug Target and Biomarker
MIR4500, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern have made it an attractive target for researchers to investigate, and its potential as a drug have piqued the interest of pharmaceutical companies.
MIR4500 is a small non-coding RNA molecule, which means it does not have a distinct 2D structure but rather a 3D shape that is determined by the arrangement of its constituent nucleotides. It is characterized by a long, linear stem-like structure that ends in a single terminal exon, which is responsible for its stability and translation into protein. MIR4500 has a calculated molecular weight of 13.9 kDa and a predicted localization in the nucleus.
MIR4500 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Its expression pattern has been observed in various tissues and organs, including brain, heart, and pancreas, and its levels have been found to be regulated by various factors, including growth factors, chemokines, and stress hormones.
One of the most promising aspects of MIR4500 is its potential as a drug target. Its unique structure and expression pattern make it an attractive target for small molecules, which can be used to modulate its activity and influence its levels in the target cells. Additionally, its role in various cellular processes makes it an attractive target for drugs that target signaling pathways involved in these processes, such as the PI3K/Akt signaling pathway.
MIR4500 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression patterns have been observed in various disease-related tissues and its levels have been found to be altered in these diseases. For example, MIR4500 has been shown to be downregulated in various types of cancer, including breast, ovarian, and colorectal cancer, and its levels have been found to be increased in the tissues of individuals with these diseases.
In addition, MIR4500 has also been shown to be involved in the regulation of various cellular processes, including cell apoptosis, cell cycle progression, and inflammation. Its expression patterns have been observed in various disease-related tissues and its levels have been found to be altered in these diseases. For example, MIR4500 has been shown to be involved in the regulation of cell apoptosis in various types of cancer, including breast, ovarian, and colorectal cancer.
MIR4500 has also been shown to be involved in the regulation of inflammation in various disease-related tissues. Its expression patterns have been observed in various disease-related tissues and its levels have been found to be altered in these diseases. For example, MIR4500 has been shown to be involved in the regulation of inflammation in various types of autoimmune diseases, including rheumatoid arthritis, and its levels have been found to be increased in the tissues of individuals with these diseases.
In conclusion, MIR4500 is a small non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and expression pattern make it an attractive target for small molecules, and its potential as a drug have piqued the interest of pharmaceutical companies. Further research is needed to fully understand its role in various cellular processes and its potential as a drug.
Protein Name: MicroRNA 4500
The "MIR4500 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4500 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4500HG | MIR4501 | MIR4504 | MIR4505 | MIR4506 | MIR4507 | MIR4508 | MIR4509-1 | MIR4509-2 | MIR4509-3 | MIR450A1 | MIR450A2 | MIR450B | MIR4510 | MIR4511 | MIR4512 | MIR4513 | MIR4514 | MIR4516 | MIR4519 | MIR451A | MIR451B | MIR452 | MIR4520-1 | MIR4520-2 | MIR4521 | MIR4524A | MIR4524B | MIR4525 | MIR4526 | MIR4527 | MIR4527HG | MIR4529 | MIR4530 | MIR4531 | MIR4533 | MIR4534 | MIR4535 | MIR4536-1 | MIR4536-2 | MIR4537 | MIR4538 | MIR4539 | MIR454 | MIR4540 | MIR455 | MIR4632 | MIR4633 | MIR4634 | MIR4635 | MIR4638 | MIR4639 | MIR4640 | MIR4641 | MIR4642 | MIR4644 | MIR4645 | MIR4646 | MIR4647 | MIR4648 | MIR4649 | MIR4650-1 | MIR4650-2 | MIR4651 | MIR4652 | MIR4653 | MIR4655 | MIR4656 | MIR4657 | MIR4658 | MIR4659A | MIR4659B | MIR466 | MIR4660 | MIR4661 | MIR4662A | MIR4663 | MIR4664 | MIR4665 | MIR4666A | MIR4666B | MIR4667 | MIR4668 | MIR4669 | MIR4670 | MIR4671 | MIR4672 | MIR4673 | MIR4674 | MIR4675 | MIR4676 | MIR4677 | MIR4679-1 | MIR4679-2 | MIR4680 | MIR4681 | MIR4684 | MIR4685 | MIR4686 | MIR4687
